Proscia Partners with Samsung Medical Center to Research Predictive Medicine in Cancer Diagnosis and Treatment
Baltimore, MD — Proscia Inc., a data solutions provider for digital pathology, and Samsung Medical Center, South Korea’s preeminent clinical and biomedical research institute, today announced a partnership focused on developing tools that enable predictive medicine in the fight against cancer. The goal of the collaboration is to leverage mathematical oncology and novel deep-learning approaches to provide predictive insight into the likelihood of lung cancer lymph node metastasis, improving physicians’ ability to prescribe targeted cancer therapies.
Advances in digital pathology have enabled the extraction of clinically relevant quantitative histological information from cancer tissue. In early results, Proscia has demonstrated the ability to use this quantitative histology to determine the likelihood of lymph node metastasis in breast cancer. In the first phase of its collaboration with Samsung Medical Center, Proscia will develop an automated algorithm for metastasis prediction from primary lung tumors. Over time, the two organizations will leverage Samsung Medical Center’s clinical expertise to expand metastasis prediction to multiple tumor types.
“There is currently no accurate method, neither from radiology nor molecular biomarkers, to predict lymph node metastasis,” said Dr. Insuk Sohn, Chief Senior Researcher at Samsung Medical Center. “Accurate prediction of lymph node metastasis is critical in selecting optimal patients for endoscopic resection. The collaboration between our specialists and those at Proscia will make major improvements in the clinical decision process and ultimately save patients’ lives.”
“As cancer treatment shifts towards new therapies and procedures and are less invasive and more precise, the importance of having a clear understanding of each patient’s individual cancer has increased as well,” said Hunter Jackson, Chief Scientific Officer at Proscia Inc. “This partnership leverages the combined power of quantitative histology and machine learning to generate insights that can give a more complete picture of a patient’s cancer.”
While the initial target of this partnership is the prediction of lymph node metastasis in lung cancer, validation of this initial product will open the door to similar endeavors in other cancers. “Once the pipeline is setup, there are many applications in different tumor types such as hepatocellular carcinoma and gynecological cancers,” said Dr. Chang Ohk Sung, Assistant Professor in the Department of Pathology at the Asan Medical Center and a member of the collaboration team.
Proscia has amassed experience in the development and deployment of tools that drive insight about cancer. The results from Proscia’s active collaborations with research departments at several major academic medical centers across the United States have had major clinical implications and pushed the boundaries of the understanding of cancer. These successes were made possible by the execution of a seed round of funding raised last year. The company recently launched image analysis applications on its platform that enable pathologists and researchers to extract meaningful information from whole slide images and power their own studies. Its partnership with the Samsung Medical Center advances Proscia’s vision of improving clinical outcomes and accelerating the discovery of breakthrough advancements in the fight against cancer.
Proscia was founded in 2014 by a team out of Johns Hopkins, the Moffitt Cancer Center, and the University of Pittsburgh to improve clinical outcomes and accelerate the discovery of breakthrough advancements in the fight against cancer. Using modern computing technologies that unlock hidden data not visible to the human eye and turning that data into valuable insights in the fight against cancer, the company is dedicated to improving the efficiency, speed and quality of pathology diagnostics and research. To learn more, please visit http://www.proscia.com.
About Samsung Medical Center
Based in Seoul, Korea, the SMC was established in 1994 and includes a cancer treatment center and a hospital. The hospital is situated in a cleverly designed building with a floor space of more than 200,000 sq.m over 5 floors underground and 20 floors above ground. It accommodates 1,306 beds, 10 specialist centers, 40 departments and 120 special clinics. The separate cancer center has a floor space of more than 100,000 sq.m and accommodates 655 beds, with 8 floors underground and 11 floors above ground. This tertiary hospital employs around 7,400 people including more than 2,300 nurses and 1,200 doctors. SMC has developed and implemented a sophisticated model and intends to become a patient-centered hospital.
Category: Anatomic Pathology, Business, Clinical Laboratories, Clinical Pathology, Cloud Computing, Data Management, Device Manufacturers, Digital Pathology News, Histology, Image Analysis, Informatics, International, Laboratory Informatics, Laboratory Management & Operations, Medical Research, Pathology News, Vendor products, Web/Tech, Whole slide